{"id":"NCT00447278","sponsor":"Eli Lilly and Company","briefTitle":"A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents","officialTitle":"A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning Using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder in Treatment-Naïve Children and Adolescents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2009-03","completion":"2009-07","firstPosted":"2007-03-14","resultsPosted":"2010-04-20","lastUpdate":"2010-04-27"},"enrollment":399,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Atomoxetine","otherNames":["LY139603","Strattera"]},{"type":"DRUG","name":"Other standard therapy for ADHD","otherNames":[]}],"arms":[{"label":"Atomoxetine","type":"EXPERIMENTAL"},{"label":"OEST","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate that atomoxetine is superior to other early standard therapy (any treatment that investigator considers is appropriate to initiate for the treatment of Attention-Deficit/Hyperactivity Disorder \\[ADHD\\]) on the long term functioning in approximately 400 children and adolescents with ADHD. Patients will be pharmacological naïve prior to entry into the study.","primaryOutcome":{"measure":"Change From Baseline to 6 Month Endpoint in Child Health and Illness Profile - Child Edition, Parent Report Form (CHIP-CE PRF), Achievement Domain","timeFrame":"Baseline, 6 months","effectByArm":[{"arm":"Atomoxetine","deltaMin":28,"sd":12.04},{"arm":"OEST","deltaMin":28.3,"sd":12.28}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":35,"countries":["Belgium","France","Ireland","Italy","Mexico","Norway","Spain","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":199},"commonTop":["Headache","Anorexia","Decreased appetite","Abdominal pain","Nausea"]}}